Publications by authors named "Karl Haslam"

Claim this Profile
I
International external quality assurance of JAK2 V617F quantification.
Julia Asp, Vibe Skov, Beatriz Bellosillo, Thomas Kristensen, Eric Lippert, Karl Haslam

Ann Hematol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutrophilia and the JAK2 V617F Mutation.
Stephen E Langabeer, Karl Haslam

Pathol Oncol Res· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An acquired NRAS mutation contributes to neutrophilic progression in a patient with primary myelofibrosis.
Stephen E Langabeer, Karl Haslam, Emma Groarke, Eibhlin Conneally

Br J Haematol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
False-negative mutation in a suspected myeloproliferative neoplasm: identification, resolution and corrective action.
Karl Haslam, Sarah Dell, Emer Atkinson, Helen Enright, Patrick Thornton

J Clin Pathol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protracted Clonal Trajectory of a V617F-Positive Myeloproliferative Neoplasm Developing during Long-Term Remission from Acute Myeloid Leukemia.
Stephen E Langabeer, Karl Haslam, Maria Anne Smyth, John Quinn, Philip T Murphy

Case Rep Hematol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.
Thomas Frawley, Cathal P O'Brien, Eibhlin Conneally, Elisabeth Vandenberghe, Melanie Percy, Karl Haslam

Genet Test Mol Biomarkers· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic Myeloid Leukemia with an e6a2 Fusion Transcript: Cooperating Mutations at Blast Crisis and Molecular Monitoring.
Mireille Crampe, Karl Haslam, Emma Groarke, Eileen Kelleher, Derville O'Shea

Case Rep Hematol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel molecular assay using hybridisation probes and melt curve analysis for exon 9 mutation detection in myeloproliferative neoplasms.
Thomas Keaney, Louise O'Connor, Janusz Krawczyk, Moutaz A Abdelrahman, Amjad H Hayat, Karl Haslam

J Clin Pathol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isolated erythrocytosis associated with a CALR mutation.
Stephen E Langabeer, Karl Haslam, Catherine M Flynn

Blood Cells Mol Dis· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of a novel variant BCR-ABL1 fusion transcript in a patient with chronic myeloid leukemia: Implications for molecular monitoring.
Mireille Crampe, Karl Haslam, Johanna Kelly, Eibhlin Conneally, Stephen E Langabeer

Hematol Oncol Stem Cell Ther· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The mutant CALR allele burden in essential thrombocythemia at transformation to acute myeloid leukemia.
Stephen E Langabeer, Karl Haslam, Ezzat Elhassadi

Blood Cells Mol Dis· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Who to screen for calreticulin mutations? An audit of real-life practice and review of current evidence.
Karl Haslam, Stephen E Langabeer

Eur J Intern Med· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Investigation of a Suspected Myeloproliferative Neoplasm in Patients with Basophilia.
Stephen E Langabeer, Karl Haslam

J Clin Diagn Res· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The JAK2 V617F mutation and thrombocytopenia.
Stephen E Langabeer, Karl Haslam

Hematol Oncol Stem Cell Ther· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches.
Karl Haslam, Stephen E Langabeer

Biomed Res Int· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted next-generation sequencing of familial platelet disorder with predisposition to acute myeloid leukaemia.
Karl Haslam, Stephen E Langabeer, Amjad Hayat, Eibhlin Conneally, Elisabeth Vandenberghe

Br J Haematol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inter-Laboratory Evaluation of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia.
Karl Haslam, Mark A Catherwood, Edwina Dobbin, Anne Sproul, Stephen E Langabeer

Mol Diagn Ther· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CALR mutation profile in Irish patients with myeloproliferative neoplasms.
Karl Haslam, Eibhlin Conneally, Catherine M Flynn, Mary R Cahill, Oonagh Gilligan

Hematol Oncol Stem Cell Ther· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reflexive Screening for BCR-ABL1 Kinase Domain Mutations in Chronic Myeloid Leukemia.
Stephen E Langabeer, Sarah L McCarron, Karl Haslam, Lisa Preston

Clin Lab· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capricious CALR mutated clones in myeloproliferative neoplasms.
Karl Haslam, Eibhlin Conneally, Stephen E Langabeer

Blood Cells Mol Dis· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute Lymphoblastic Leukemia Arising in CALR Mutated Essential Thrombocythemia.
Stephen E Langabeer, Karl Haslam, David O'Brien, Johanna Kelly, Claire Andrews

Case Rep Hematol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The JAK2 V617F Allele Burden in Latent Myeloproliferative Neoplasms Presenting with Splanchnic Vein Thrombosis.
Matthew Goodyer, Stephen E Langabeer, Karl Haslam, Karen Murphy

Pathol Oncol Res· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular diagnostics of myeloproliferative neoplasms.
Stephen E Langabeer, Hajnalka Andrikovics, Julia Asp, Beatriz Bellosillo, Serge Carillo, Karl Haslam

Eur J Haematol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evading Capture by Residual Disease Monitoring: Extramedullary Manifestation of JAK2 V617F-Positive Primary Myelofibrosis After Allogeneic Stem Cell Transplantation.
Stephen E Langabeer, James Nolan, Karl Haslam, Lindsey Clarke, Richard Flavin

Case Rep Hematol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
To screen for CALR mutations in patients with splanchnic vein thrombosis?
Karl Haslam, Stephen E Langabeer

Clin Lab· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis